RxDoctor Payments Data

Spiro Combest, MD

Ophthalmology · Westport, CTNPI 1194934216

Payments from drug & device makers

$2,264in general payments, 2019–2025

Across 90 payments — averaging $25.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$502
  • Alcon$452
  • Sun Pharmaceutical Industries Inc.$303
  • Bausch & Lomb Americas Inc.$137
  • Novartis$133
  • Kala Pharmaceuticals, Inc.$120
  • plus $618 from 15 others

What the payments were for

  • Food & beverage$2,264100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,264 in reported general payments places this provider in the 70th percentile of 279 ophthalmology providers in Connecticut.

See all ophthalmology providers in Connecticut

Medicare billing

Part B allowed, 2024
$111,437
Medicare patients
540
Services billed
1,316

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine50$59,634
XiidraLifitegrast13$20,304
LumiganBimatoprost34$19,457
MieboPerfluorohexyloctane/Pf20$15,273
CequaCyclosporine13$13,209
Cyclosporine17$7,174
CombiganBrimonidine Tartrate/Timolol11$5,824
Prednisolone Acetate125$3,381
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha258$2,557
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol22$1,545
Latanoprost88$1,088
Ofloxacin81$733
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat32$544
Timolol Maleate32$323
Cephalexin12$182

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$502$84,91495 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$137$35,57733 claims
Sun Pharmaceutical Industries Inc.Cequa$303$13,20913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 279 ophthalmology providers in Connecticut.

Other ophthalmology in Westport

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →